Ho M-Y, Body S, Kheramin S, Bradshaw C M, Szabadi E
Psychopharmacology Section, Division of Psychiatry, University of Nottingham, Room B109, Medical School, Queen's Medical Centre, NG7 2UH, Nottingham, UK.
Psychopharmacology (Berl). 2003 May;167(2):137-44. doi: 10.1007/s00213-002-1375-9. Epub 2003 Mar 25.
Performance on progressive-ratio schedules has been proposed as a means of assessing the effects of drugs on motivation. We have adopted a mathematical model proposed by Killeen to analyse the effects of drugs acting at 5-HT(1A) receptors on progressive-ratio performance. According to this model, the relationship between response rate and ratio size is described by a bitonic (inverted-U) function. One parameter of the function, a, expresses the motivational or "activating" effect of the reinforcer (duration of activation of responding produced by the reinforcer), whereas another parameter, delta, expresses the minimum time needed to execute a response and is regarded as an index of "motor capacity".
To examine the effect of the selective 5-HT(1A) receptor agonist 8-OH-DPAT [8-hydroxy-2-(di- n-propylamino)tetralin] and the antagonist WAY-100635 [ N-[2-(4-[2-methoxyphenyl]-1-piperazinyl)ethyl]- N-2-pyridinylcyclo-hexanecarboxamide] on progressive-ratio schedule performance.
Sixteen rats responded for a food-pellet reinforcer on a time-constrained progressive-ratio schedule (55-min sessions). In phase 1, they received single doses (s.c.) of 8-OH-DPAT (25, 50, 100, 200 microg kg(-1), four treatments at each dose) or the vehicle (0.9% saline solution). In phase 2, they received WAY-100635 (30, 100, 300 microg kg(-1)) according to the same regimen. In phase 3, they received 8-OH-DPAT (100 microg kg(-1)) alone or in combination with WAY-100635 (30 microg kg(-1)). 8-OH-DPAT dose dependently increased the value of a, significant increases being seen with the 50, 100 and 200 microg kg(-1) doses. The highest dose also increased delta. WAY-100635 did not significantly alter either a or delta. WAY-100635 significantly attenuated the effect of 8-OH-DPAT on both a and delta.
The results suggest that 8-OH-DPAT enhanced the activating effect of the reinforcer (the highest dose may also have induced motor debilitation). The finding that the effect of 8-OH-DPAT on a was attenuated by WAY-100635 implicates 5-HT(1A) receptors in this effect. The results are consistent with previous reports that 8-OH-DPAT facilitates feeding and food-reinforced operant responding in rats and suggest that these effects may be brought about by an increase in food motivation.
渐进比率程序上的表现已被提议作为评估药物对动机影响的一种方法。我们采用了基林提出的数学模型来分析作用于5-羟色胺(5-HT)1A受体的药物对渐进比率表现的影响。根据该模型,反应率与比率大小之间的关系由一个双调(倒U形)函数描述。该函数的一个参数a表示强化物的动机或“激活”作用(强化物产生的反应激活持续时间),而另一个参数δ表示执行一次反应所需的最短时间,并被视为“运动能力”指标。
研究选择性5-HT1A受体激动剂8-羟基-2-(二正丙基氨基)四氢萘(8-OH-DPAT)和拮抗剂N-[2-(4-[2-甲氧基苯基]-1-哌嗪基)乙基]-N-2-吡啶基环己烷甲酰胺(WAY-100635)对渐进比率程序表现的影响。
16只大鼠在限时渐进比率程序(55分钟时段)上对食物颗粒强化物做出反应。在第1阶段,它们接受单剂量(皮下注射)的8-OH-DPAT(25、50、100、200微克/千克,每个剂量四种处理)或赋形剂(0.9%盐溶液)。在第2阶段,它们按照相同方案接受WAY-100635(30、100、300微克/千克)。在第3阶段,它们单独接受8-OH-DPAT(100微克/千克)或与WAY-100635(30微克/千克)联合接受。8-OH-DPAT剂量依赖性地增加a值,50、100和200微克/千克剂量时可见显著增加。最高剂量也增加了δ。WAY-100635对a或δ均无显著改变。WAY-100635显著减弱了8-OH-DPAT对a和δ的影响。
结果表明8-OH-DPAT增强了强化物的激活作用(最高剂量可能还诱导了运动能力减弱)。WAY-100635减弱8-OH-DPAT对a的影响这一发现表明5-HT1A受体参与了此效应。这些结果与先前关于8-OH-DPAT促进大鼠进食和食物强化操作性反应的报道一致,并表明这些效应可能是由食物动机增加引起的。